Business Standard

Gland Pharma Ltd Announcements

BY EXCHANGE :

ANNOUNCEMENTSUBJECTATTACHMENTBROADCAST DATE
Board Meeting Intimation for Declaration Of Audited Financial Results For The Quarter And Financial Year Ended 31.03.2024 And To Consider And Recommend The Payment Of Final Dividend For FY 2023-24 Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of t...Read More09/05/2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Gland Pharma receives approval for Edaravone Injection07/05/2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Gland Pharma receives approval from USFDA for Plerixafor for Injection07/05/2024
Announcement under Regulation 30 (LODR)-Change in Management Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer29/04/2024
Board Meeting Outcome for Outcome Of Board Meeting Held On April 29 2024 Outcome of Board Meeting held on April 29 202429/04/2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Gland Pharma receives approval for Cetrorelix Acetate for Injection29/04/2024
PCS Certificate U/R 40(9) For The Year Ended 31.03.2024 PCS Certificate u/r 40(9) for the year ended 31.03.202417/04/2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substan...Read More13/04/2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substan...Read More13/04/2024
Compliance Certificate U/R 7(3) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2024 Compliance Certificate u/r 7(3) of SEBI (LODR) Regulations 2015 for the year end...Read More10/04/2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 201810/04/2024
Clarification Regarding Increase In Volumes Clarification regarding increase in volumes10/04/2024
Clarification sought from Gland Pharma Ltd The Exchange has sought clarification from Gland Pharma Ltd on April 10 2024 wit...Read More10/04/2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Gland Pharma receives approval for Eribulin Mesylate Injection06/04/2024
Closure of Trading Window Trading Window of the Company will be closed w.e.f 27.03.2024 until 48 hours of ...Read More26/03/2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation regarding schedule of investor Meet on 26.03.202425/03/2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of 2400 Equity Shares on exercise of ESOP25/03/2024
Announcement under Regulation 30 (LODR)-Change in Management Changes among Senior Management Personnel of the Company25/03/2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Schedule of Investor Meeting on 21.03.202419/03/2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation regarding Investor Meets Scheduled on 19.03.2024 and 20.03.202414/03/2024

Load more